S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:PDSB

PDS Biotechnology - PDSB Stock Forecast, Price & News

$9.78
+0.75 (+8.31%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.81
$10.06
50-Day Range
$2.97
$9.78
52-Week Range
$2.89
$10.06
Volume
978,539 shs
Average Volume
1.80 million shs
Market Capitalization
$278.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.25

PDS Biotechnology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
55.9% Upside
$15.25 Price Target
Short Interest
Bearish
5.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.04mentions of PDS Biotechnology in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.06) to ($1.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

834th out of 1,047 stocks

Pharmaceutical Preparations Industry

405th out of 512 stocks

PDSB stock logo

About PDS Biotechnology (NASDAQ:PDSB) Stock

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

Receive PDSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PDSB Stock News Headlines

PDS Biotechnology (NASDAQ:PDSB) PT Raised to $19.00
US Stocks Mostly Lower; Nasdaq Drops Over 100 Points
PDS Biotech: Strong Data Indicate Further Upside
PDS Biotech to Present at the LD Micro Main Event XV
See More Headlines
Receive PDSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PDSB Company Calendar

Last Earnings
11/10/2021
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PDSB
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.25
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+55.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-16,920,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.65 per share

Miscellaneous

Free Float
25,983,000
Market Cap
$278.34 million
Optionable
Not Optionable
Beta
2.69

Key Executives

  • Dr. Frank K. Bedu-Addo Ph.D. (Age 57)
    Pres, CEO & Director
    Comp: $714.08k
  • Mr. Matthew C. Hill CPAMr. Matthew C. Hill CPA (Age 53)
    CFO, Principal Financial & Accounting Officer
    Comp: $194.29k
  • Dr. Gregory L. Conn Ph.D. (Age 67)
    Chief Scientific Officer
    Comp: $220.46k
  • Ms. Lauren V. Wood M.D. (Age 62)
    Chief Medical Officer
    Comp: $444.99k
  • Dr. Joe J. Dervan
    VP of R&D
  • Ms. Deanne Randolph
    VP of Commercial Devel. & Head of Investor Relations
  • Mr. Spencer Brown J.D.
    Sr. VP & Gen. Counsel
  • Ms. Nathalie Riebel
    Sr. VP of Clinical Operations
  • Mr. Sanjay Zaveri
    Sr. VP of Bus. Devel.
  • Ms. Janetta Trochimiuk (Age 59)
    Controller













PDSB Stock - Frequently Asked Questions

Should I buy or sell PDS Biotechnology stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PDS Biotechnology in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PDSB shares.
View PDSB analyst ratings
or view top-rated stocks.

What is PDS Biotechnology's stock price forecast for 2023?

4 brokers have issued twelve-month target prices for PDS Biotechnology's stock. Their PDSB share price forecasts range from $10.00 to $19.00. On average, they predict the company's stock price to reach $15.25 in the next twelve months. This suggests a possible upside of 55.9% from the stock's current price.
View analysts price targets for PDSB
or view top-rated stocks among Wall Street analysts.

How have PDSB shares performed in 2022?

PDS Biotechnology's stock was trading at $8.10 at the start of the year. Since then, PDSB shares have increased by 20.7% and is now trading at $9.78.
View the best growth stocks for 2022 here
.

When is PDS Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our PDSB earnings forecast
.

How were PDS Biotechnology's earnings last quarter?

PDS Biotechnology Co. (NASDAQ:PDSB) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.02. During the same quarter in the previous year, the firm posted ($0.23) earnings per share.

What other stocks do shareholders of PDS Biotechnology own?
What is PDS Biotechnology's stock symbol?

PDS Biotechnology trades on the NASDAQ under the ticker symbol "PDSB."

Who are PDS Biotechnology's major shareholders?

PDS Biotechnology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.03%), BlackRock Inc. (1.65%), Two Sigma Advisers LP (1.45%), Renaissance Technologies LLC (1.13%), Two Sigma Investments LP (1.05%) and Commonwealth Equity Services LLC (0.21%). Insiders that own company stock include Delyle W Bloomquist, Matthew C Hill, Steve C Glover and Voorhees Seth Van.
View institutional ownership trends
.

How do I buy shares of PDS Biotechnology?

Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PDS Biotechnology's stock price today?

One share of PDSB stock can currently be purchased for approximately $9.78.

How much money does PDS Biotechnology make?

PDS Biotechnology (NASDAQ:PDSB) has a market capitalization of $278.33 million. The company earns $-16,920,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How can I contact PDS Biotechnology?

PDS Biotechnology's mailing address is 25B Vreeland Road, Florham Park NJ, 07932. The official website for the company is www.pdsbiotech.com. The company can be reached via phone at (800) 208-3343, via email at ir@edgetherapeutics.com, or via fax at 908-790-1212.

This page (NASDAQ:PDSB) was last updated on 12/2/2022 by MarketBeat.com Staff